中国实用内科杂志2024，Vol.44Issue(1)：33-41,9.DOI:10.19538/j.nk2024010107
血液系统疾病超说明书适应证用药辽宁省专家共识(2023版)
Expert consensus on off-label drug use of Liaoning province in hematological diseases(2023 edition)
摘要
Abstract
With the continuous development of molecular detection techniques,the diagnostic rate of hematological diseases is rising.The drug treatment of hematological diseases,especially malignant hematological diseases,also develops rapidly,benefiting more and more patients clinically.The standardized diagnosis and treatment of hematological diseases and the rational drug use,especially the new immunotherapy and targeted therapy drugs,have been widely concerned by clinicians and patients.Off-label drugs use is common in clinical practice.The implementation of the Law on Doctors of the People's Republic of China effective on March 2022 provides a legal basis for off-label drug use in China.Expert Consensus on Off-Label Drug Use of Liaoning Province in Hematological Diseases(2023 Edition)has compiled a list of off-label drugs for chemotherapy,targeted drugs and supportive care for hematological disorders.According to the evidence-based evaluation method developed by the expert group,this list is condensed through literature review,evidence quality evaluation grading and expert argumentation,to provide evidence-based support and reference for clinical medication.关键词
超说明书用药/血液系统疾病/共识Key words
off-label drug use/hematological diseases/consensus分类
医药卫生引用本文复制引用
辽宁省免疫学会淋巴系统基础与临床免疫分会,杨威..血液系统疾病超说明书适应证用药辽宁省专家共识(2023版)[J].中国实用内科杂志,2024,44(1):33-41,9.基金项目
辽宁省自然科学基金指导计划(20180550879) （20180550879）
